Skip to main navigation Skip to search Skip to main content

SAFETY, TOLERABILITY, & IMMUNOGENICITY OF TWO 2X40-MCG REGIMENS OF RECOMBIVAX HB, PROTOCOL 050, STUDY 050-002

SUNY Downstate Health Sciences University

Project: Research

Project Details

StatusFinished
Effective start/end date05/28/99 → 05/27/01

Funding

  • Merck and Company: $29,244.50